{"hands_on_practices": [{"introduction": "To develop better pain therapies, it's crucial to understand that not all pain is the same. Pharmacologists use specific experimental models to distinguish between acute pain from a direct injury and chronic pain states that involve changes in the central nervous system, a process known as central sensitization. This exercise introduces the rodent formalin test, a classic preclinical model that allows us to see these two phases of pain distinctly, and challenges you to predict how different non-opioid central analgesics work based on their underlying mechanisms [@problem_id:4966198]. Mastering this connection between mechanism and experimental outcome is a foundational skill for drug discovery and evaluation.", "problem": "A researcher is designing a study using the rodent formalin test to differentiate drug effects on acute nociception versus central sensitization. The study will evaluate four non-opioid, centrally acting analgesics administered at sub-sedative doses: acetaminophen, nefopam, gabapentin, and subanesthetic ketamine. The researcher will separately quantify the immediate-early pain behavior and the delayed tonic pain behavior that follows after a quiescent interval. Using only foundational definitions of the formalin test phases and first-principles reasoning about the neurophysiology targeted by each drug class (for example, the role of dorsal horn glutamatergic plasticity, N-Methyl-D-aspartate (NMDA) receptor-dependent wind-up, and descending monoaminergic inhibition), select the option that correctly defines the phases of the formalin test and maps which of the listed non-opioid central analgesics predominantly reduce the delayed tonic phase compared with the immediate-early phase.\n\nA. Phase I is the immediate-early pain behavior from $0$ to $5$ minutes driven primarily by direct activation of peripheral nociceptors and a C-fiber discharge; an interphase of relative quiescence spans approximately $5$ to $15$ minutes; Phase II is the delayed tonic pain from $15$ to $60$ minutes driven by spinal cord central sensitization with a contribution from peripheral inflammation. At sub-sedative doses, acetaminophen, nefopam, gabapentin, and subanesthetic ketamine predominantly reduce Phase II more than Phase I.\n\nB. Phase I is the delayed tonic pain from $15$ to $60$ minutes driven by central sensitization, and Phase II is the immediate-early pain from $0$ to $5$ minutes; there is no distinct interphase. At sub-sedative doses, acetaminophen and nefopam predominantly reduce Phase I, while gabapentin and subanesthetic ketamine reduce Phase II.\n\nC. Phase I is the immediate-early pain behavior from $0$ to $5$ minutes, followed by an interphase, then Phase II from $15$ to $60$ minutes; however, acetaminophen and gabapentin predominantly reduce Phase I due to rapid attenuation of nociceptor discharge, ketamine reduces both phases equally, and nefopam predominantly reduces Phase II.\n\nD. Phase I is the immediate-early pain behavior from $0$ to $5$ minutes and Phase II the delayed tonic phase from $15$ to $60$ minutes, with an interphase between them; acetaminophen predominantly reduces Phase I through peripheral cyclooxygenase (COX) inhibition, nefopam predominantly reduces Phase I via sodium channel blockade, gabapentin predominantly reduces Phase II, and subanesthetic ketamine predominantly reduces Phase I by suppressing initial afferent input.", "solution": "The problem statement has been critically validated and is deemed valid. It is scientifically grounded, well-posed, and objective, providing a clear question based on established principles in pharmacology and neuroscience.\n\nThe problem requires a two-part analysis: first, defining the phases of the rodent formalin test, and second, predicting the differential effects of four non-opioid central analgesics on these phases based on their neurophysiological mechanisms of action.\n\n**Part 1: Foundational Principles of the Formalin Test**\n\nThe formalin test is a standard preclinical model of tonic pain that involves injecting a dilute solution of formalin into a rodent's paw. This induces a characteristic biphasic pattern of nocifensive behaviors (e.g., licking, flinching, biting the affected paw).\n\n1.  **Phase $I$ (Immediate-Early Phase):** This phase occurs immediately following the injection and typically lasts for the first $5$ to $10$ minutes. The problem specifies a window of $0$ to $5$ minutes, which is a common convention for quantification. This phase reflects acute nociceptive pain.\n    *   **Neurophysiological Basis:** Phase $I$ is caused by the direct chemical activation of peripheral nociceptors, particularly Transient Receptor Potential Ankyrin $1$ (TRPA$1$) and Transient Receptor Potential Vanilloid $1$ (TRPV$1$) channels on C-fibers and A$\\delta$-fibers. This generates an intense, synchronous barrage of action potentials that travel up the afferent nerves to the dorsal horn of the spinal cord, causing the perception of sharp, acute pain.\n\n2.  **Interphase:** Following Phase $I$, there is a quiescent period, typically lasting from approximately minute $5$ to minute $15$. During this interval, pain behaviors significantly decrease or cease.\n\n3.  **Phase $II$ (Delayed Tonic Phase):** This phase begins around $15$ to $20$ minutes post-injection and can persist for $45$ to $90$ minutes. The problem specifies a window of $15$ to $60$ minutes. This phase is considered a model for inflammatory pain and, crucially, for central sensitization.\n    *   **Neurophysiological Basis:** The mechanisms of Phase $II$ are more complex than those of Phase $I$. They involve a combination of:\n        *   **Peripheral Inflammation:** The formalin induces a local inflammatory response in the paw, releasing inflammatory mediators (e.g., prostaglandins, bradykinin) that sensitize peripheral nociceptors.\n        *   **Central Sensitization:** The intense afferent barrage during Phase $I$ triggers activity-dependent neuroplastic changes in the dorsal horn. A key event is the robust release of glutamate from presynaptic terminals, which acts on postsynaptic neurons. This intense stimulation removes the voltage-dependent magnesium ($Mg^{2+}$) block from N-Methyl-D-aspartate ($NMDA$) receptors. The subsequent influx of calcium ($Ca^{2+}$) through opened $NMDA$ receptor channels activates intracellular signaling cascades, leading to the phosphorylation of receptors and ion channels. This process, known as \"wind-up,\" results in a state of hyperexcitability where spinal neurons have amplified responses to subsequent afferent input.\n\nIn summary, drugs that primarily affect acute nociception (e.g., by blocking peripheral nerve conduction) would be expected to inhibit Phase $I$. In contrast, drugs that interfere with the mechanisms of central sensitization or that enhance descending pain inhibition are expected to predominantly inhibit Phase $II$.\n\n**Part 2: Analysis of Drug Mechanisms and Predicted Effects**\n\nThe problem asks which of the listed drugs, administered at sub-sedative doses, would predominantly reduce Phase $II$ compared with Phase $I$.\n\n1.  **Subanesthetic Ketamine:**\n    *   **Mechanism:** Ketamine is a non-competitive antagonist of the $NMDA$ receptor. It blocks the ion channel pore, preventing $Ca^{2+}$ influx even when the receptor is activated by glutamate and glycine.\n    *   **Predicted Effect:** The development and expression of central sensitization in Phase $II$ are critically dependent on $NMDA$ receptor activation. By blocking these receptors, ketamine directly prevents the \"wind-up\" phenomenon. Therefore, it is a classic inhibitor of Phase $II$ of the formalin test, with a much smaller effect, if any, on the initial nociceptive barrage of Phase $I$. It will predominantly reduce Phase $II$.\n\n2.  **Gabapentin:**\n    *   **Mechanism:** Gabapentin binds with high affinity to the $\\alpha_2\\delta-1$ subunit of presynaptic voltage-gated calcium channels ($VGCC$s) in the central nervous system. This binding disrupts the forward trafficking of these channels to the presynaptic terminal, leading to a reduced density of functional $VGCC$s.\n    *   **Predicted Effect:** A reduction in presynaptic $VGCC$ function decreases $Ca^{2+}$ influx upon arrival of an action potential. This, in turn, reduces the release of excitatory neurotransmitters, most notably glutamate, into the synaptic cleft of the dorsal horn. By dampening glutamatergic transmission, gabapentin effectively limits the necessary stimulus for inducing and maintaining central sensitization. It will therefore predominantly reduce Phase $II$.\n\n3.  **Nefopam:**\n    *   **Mechanism:** Nefopam is a centrally acting analgesic whose primary mechanism is the inhibition of serotonin and norepinephrine reuptake in the synaptic cleft.\n    *   **Predicted Effect:** This action enhances the function of the descending monoaminergic pain-inhibitory pathways that originate in the brainstem and project to the spinal dorsal horn. These pathways exert an inhibitory effect on nociceptive transmission, acting as a \"brake\" on spinal hyperexcitability. By strengthening this endogenous inhibitory system, nefopam directly counteracts the processes of central sensitization. Thus, it is expected to predominantly reduce Phase $II$.\n\n4.  **Acetaminophen (Paracetamol):**\n    *   **Mechanism:** The mechanism of acetaminophen is complex and not fully elucidated, but it is considered to act primarily within the central nervous system. While it is a weak inhibitor of cyclooxygenase ($COX$) enzymes, its main analgesic effect is not attributed to peripheral anti-inflammatory action. Evidence strongly suggests it acts by potentiating descending serotonergic pathways, similar in effect to nefopam, and may also involve modulation of endocannabinoid and TRPV$1$ systems within the CNS.\n    *   **Predicted Effect:** Given its central mechanisms, particularly the enhancement of descending inhibition, acetaminophen is expected to effectively modulate the central processing of pain. This action would be most impactful against the centrally-mediated hyperexcitability of Phase $II$. Therefore, it is expected to predominantly reduce Phase $II$ more than Phase $I$.\n\n**Conclusion of Derivation:** All four drugs — ketamine, gabapentin, nefopam, and acetaminophen — exert their primary analgesic effects through central mechanisms that counteract central sensitization or enhance descending inhibition. Consequently, all four are predicted to predominantly reduce the delayed tonic phase (Phase $II$) of the formalin test more than the immediate-early phase (Phase $I$).\n\n**Option-by-Option Analysis**\n\n*   **A. Phase I is the immediate-early pain behavior from $0$ to $5$ minutes driven primarily by direct activation of peripheral nociceptors and a C-fiber discharge; an interphase of relative quiescence spans approximately $5$ to $15$ minutes; Phase II is the delayed tonic pain from $15$ to $60$ minutes driven by spinal cord central sensitization with a contribution from peripheral inflammation. At sub-sedative doses, acetaminophen, nefopam, gabapentin, and subanesthetic ketamine predominantly reduce Phase II more than Phase I.**\n    *   The definition of the phases and their underlying mechanisms is correct.\n    *   The mapping of the drug effects is correct, as all four drugs act centrally to inhibit processes underlying Phase $II$ (central sensitization, descending modulation). This statement is fully consistent with the first-principles derivation.\n    *   **Verdict: Correct.**\n\n*   **B. Phase I is the delayed tonic pain from $15$ to $60$ minutes driven by central sensitization, and Phase II is the immediate-early pain from $0$ to $5$ minutes; there is no distinct interphase. At sub-sedative doses, acetaminophen and nefopam predominantly reduce Phase I, while gabapentin and subanesthetic ketamine reduce Phase II.**\n    *   The definition of the phases is fundamentally incorrect; it has them reversed and incorrectly denies the existence of the interphase. The entire premise is flawed.\n    *   **Verdict: Incorrect.**\n\n*   **C. Phase I is the immediate-early pain behavior from $0$ to $5$ minutes, followed by an interphase, then Phase II from $15$ to $60$ minutes; however, acetaminophen and gabapentin predominantly reduce Phase I due to rapid attenuation of nociceptor discharge, ketamine reduces both phases equally, and nefopam predominantly reduces Phase II.**\n    *   The phase definition is correct.\n    *   The drug mapping is incorrect. Gabapentin's mechanism does not predominantly affect Phase $I$. Ketamine's signature effect is a profound and selective reduction of Phase $II$, not an equal reduction of both phases.\n    *   **Verdict: Incorrect.**\n\n*   **D. Phase I is the immediate-early pain behavior from $0$ to $5$ minutes and Phase II the delayed tonic phase from $15$ to $60$ minutes, with an interphase between them; acetaminophen predominantly reduces Phase I through peripheral cyclooxygenase (COX) inhibition, nefopam predominantly reduces Phase I via sodium channel blockade, gabapentin predominantly reduces Phase II, and subanesthetic ketamine predominantly reduces Phase I by suppressing initial afferent input.**\n    *   The phase definition is correct.\n    *   The drug mapping and its justification are incorrect for three of the four drugs. Acetaminophen's primary action is not peripheral $COX$ inhibition. Nefopam's primary action is not sodium channel blockade. Ketamine's primary action is not on initial afferent input but on central sensitization in Phase $II$.\n    *   **Verdict: Incorrect.**\n\nBased on the analysis, only option A provides a scientifically accurate definition of the formalin test phases and a correct prediction of the drug effects based on their established central mechanisms of action.", "answer": "$$\\boxed{A}$$", "id": "4966198"}, {"introduction": "A primary goal in modern pain management is to provide effective relief while minimizing the significant side effects associated with high doses of opioids. This has led to the strategy of multimodal analgesia, where drugs with different mechanisms are combined. This practice problem models a common clinical scenario where a non-opioid central analgesic, pregabalin, is added to a morphine regimen [@problem_id:4966185]. You will calculate the \"opioid-sparing\" effect and use a pharmacodynamic model to quantify the resulting decrease in the probability of adverse effects, directly linking a pharmacological intervention to a tangible patient benefit.", "problem": "A hospital pain service introduces pregabalin, a non-opioid centrally acting analgesic that reduces central sensitization by binding the $\\alpha_2\\delta$ subunit of voltage-gated calcium channels, as an adjunct to morphine for patients with neuropathic features. In a cohort analysis, the average daily morphine requirement to maintain equivalent analgesia decreases from $60$ mg to $36$ mg after the addition of pregabalin. Using first-principles definitions, the opioid-sparing fraction is the fraction of the baseline opioid dose no longer required when the adjunct is added.\n\nTo evaluate clinical significance with respect to opioid-related adverse effects (for example, opioid-induced nausea/constipation), assume a widely used pharmacodynamic maximum-effect model where the probability of experiencing the adverse effect at a daily morphine dose $D$ mg is\n$$\nP(D) \\;=\\; P_{\\text{base}} \\;+\\; \\frac{E_{\\max}\\,D}{EC_{50} + D},\n$$\nwith baseline probability $P_{\\text{base}} = 0.10$, maximum incremental probability above baseline $E_{\\max} = 0.50$, and half-maximal effect dose $EC_{50} = 30$ mg. Compute:\n- the opioid-sparing fraction when the dose is reduced from $60$ mg to $36$ mg,\n- the absolute reduction in adverse effect probability predicted by the model when the dose changes from $60$ mg to $36$ mg.\n\nExpress both quantities as decimals without percent signs. Round your final results to four significant figures. No units are required in the final answer.", "solution": "The user has provided a problem statement that requires validation before a solution can be attempted.\n\n### Step 1: Extract Givens\n- **Baseline morphine dose:** $D_{0} = 60$ mg/day\n- **Reduced morphine dose with pregabalin:** $D_{1} = 36$ mg/day\n- **Definition of opioid-sparing fraction (OSF):** The fraction of the baseline opioid dose no longer required when the adjunct is added.\n- **Pharmacodynamic model for adverse effect probability $P(D)$:**\n$$\nP(D) \\;=\\; P_{\\text{base}} \\;+\\; \\frac{E_{\\max}\\,D}{EC_{50} + D}\n$$\n- **Model parameters:**\n  - $P_{\\text{base}} = 0.10$ (baseline probability of adverse effect)\n  - $E_{\\max} = 0.50$ (maximum incremental probability)\n  - $EC_{50} = 30$ mg (half-maximal effect dose)\n- **Required computations:**\n  1. The opioid-sparing fraction (OSF).\n  2. The absolute reduction in adverse effect probability.\n- **Output format:** Results as decimals rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is validated against the required criteria.\n\n- **Scientifically Grounded:** The problem is firmly rooted in the principles of clinical pharmacology and pharmacodynamics. The description of pregabalin's mechanism of action is accurate. The use of an $E_{\\max}$ model (a type of sigmoid dose-response model) to relate drug dose to effect probability is a standard practice in pharmacology. The concept of opioid-sparing is a well-established clinical metric. The numerical values provided for doses and model parameters are within a plausible range for clinical scenarios.\n- **Well-Posed:** The problem is well-posed. It provides clear definitions for all quantities to be calculated and includes all necessary numerical data. A unique solution can be determined.\n- **Objective:** The problem is stated in precise, objective, and technical language, free from subjective or speculative claims.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. It is scientifically sound, well-posed, and objective. A solution will be provided.\n\n### Solution Derivation\nThe problem requires computing two distinct quantities: the opioid-sparing fraction and the absolute reduction in adverse effect probability.\n\n**Part 1: Opioid-Sparing Fraction (OSF)**\n\nThe opioid-sparing fraction, $f_{\\text{OSF}}$, is defined as the fraction of the baseline opioid dose no longer required. The baseline dose is $D_{0}$ and the reduced dose is $D_{1}$. The dose reduction is the difference $D_{0} - D_{1}$. The fraction of the baseline dose that this reduction represents is:\n$$\nf_{\\text{OSF}} = \\frac{D_{0} - D_{1}}{D_{0}}\n$$\nSubstituting the given values, $D_{0} = 60$ mg and $D_{1} = 36$ mg:\n$$\nf_{\\text{OSF}} = \\frac{60 - 36}{60} = \\frac{24}{60}\n$$\nThis simplifies to:\n$$\nf_{\\text{OSF}} = \\frac{2}{5} = 0.4\n$$\nThe problem requires the answer to be expressed with four significant figures. Therefore, we write $0.4$ as $0.4000$.\n\n**Part 2: Absolute Reduction in Adverse Effect Probability ($\\Delta P$)**\n\nThe absolute reduction in the probability of an adverse effect, $\\Delta P$, is the difference between the probability at the baseline dose, $P(D_{0})$, and the probability at the reduced dose, $P(D_{1})$.\n$$\n\\Delta P = P(D_{0}) - P(D_{1})\n$$\nThe probability $P(D)$ is given by the model:\n$$\nP(D) = P_{\\text{base}} + \\frac{E_{\\max} D}{EC_{50} + D}\n$$\nUsing the provided parameters $P_{\\text{base}} = 0.10$, $E_{\\max} = 0.50$, and $EC_{50} = 30$ mg.\n\nFirst, we calculate the probability at the baseline dose, $D_{0} = 60$ mg:\n$$\nP(D_{0}) = P(60) = 0.10 + \\frac{0.50 \\times 60}{30 + 60} = 0.10 + \\frac{30}{90} = 0.10 + \\frac{1}{3}\n$$\nNext, we calculate the probability at the reduced dose, $D_{1} = 36$ mg:\n$$\nP(D_{1}) = P(36) = 0.10 + \\frac{0.50 \\times 36}{30 + 36} = 0.10 + \\frac{18}{66} = 0.10 + \\frac{3}{11}\n$$\nNow, we compute the absolute reduction $\\Delta P$:\n$$\n\\Delta P = P(D_{0}) - P(D_{1}) = \\left(0.10 + \\frac{1}{3}\\right) - \\left(0.10 + \\frac{3}{11}\\right)\n$$\nThe baseline probability term $P_{\\text{base}}$ cancels out:\n$$\n\\Delta P = \\frac{1}{3} - \\frac{3}{11}\n$$\nTo subtract the fractions, we find a common denominator, which is $3 \\times 11 = 33$:\n$$\n\\Delta P = \\frac{11}{33} - \\frac{9}{33} = \\frac{11 - 9}{33} = \\frac{2}{33}\n$$\nTo express this as a decimal, we perform the division:\n$$\n\\Delta P = \\frac{2}{33} \\approx 0.06060606...\n$$\nRounding this result to four significant figures gives $0.06061$. The first significant digit is $6$, the fourth is the second $0$. The digit that follows is $6$ ($ \\ge 5$), so we round up the last significant digit from $0$ to $1$.\n\nThe two computed quantities are:\n- Opioid-sparing fraction: $0.4000$\n- Absolute reduction in adverse effect probability: $0.06061$", "answer": "$$\n\\boxed{\\begin{pmatrix} 0.4000 & 0.06061 \\end{pmatrix}}\n$$", "id": "4966185"}, {"introduction": "Effective and safe drug therapy requires more than just choosing the right drug; it requires administering the right dose for each individual patient. Patient factors like organ function can dramatically alter how a drug is processed by the body. This exercise presents a critical real-world task: adjusting the dose of pregabalin for a patient with impaired kidney function [@problem_id:4966189]. By applying fundamental pharmacokinetic principles, you will learn how to modify a dosing regimen to maintain therapeutic drug levels while avoiding potential toxicity, a core competency in clinical pharmacology.", "problem": "A non-opioid central analgesic, pregabalin, is used to treat neuropathic pain. Consider a patient with normal renal function whose creatinine clearance is $CL_{Cr,1} = 100\\,\\text{mL/min}$. This patient is stabilized on pregabalin $D_{1} = 150\\,\\text{mg}$ administered every $\\tau = 12\\,\\text{h}$, achieving an average steady-state plasma concentration $C_{ss,\\text{avg}}$ in the middle of the therapeutic window. Assume the following widely accepted pharmacokinetic bases:\n- At steady state under linear first-order elimination, the average concentration is proportional to the dosing rate and inversely proportional to clearance.\n- Pregabalin is eliminated unchanged by the kidney with negligible nonrenal clearance, and its total body clearance scales linearly with creatinine clearance under steady-state conditions.\n- Oral bioavailability is constant across the two patients.\n\nA second patient has reduced renal function with creatinine clearance $CL_{Cr,2} = 30\\,\\text{mL/min}$. Assuming the same dosing interval $\\tau$ and the same formulation and bioavailability, determine the single dose $D_{2}$ (in milligrams) that should be administered every $12\\,\\text{h}$ to maintain the same $C_{ss,\\text{avg}}$ within the therapeutic window.\n\nExpress the final adjusted dose in milligrams. Round your answer to three significant figures.", "solution": "The problem statement is first validated against the required criteria.\n\n### Step 1: Extract Givens\n- Patient $1$ creatinine clearance: $CL_{Cr,1} = 100\\,\\text{mL/min}$\n- Patient $1$ dose: $D_{1} = 150\\,\\text{mg}$\n- Dosing interval for both patients: $\\tau = 12\\,\\text{h}$\n- Patient $2$ creatinine clearance: $CL_{Cr,2} = 30\\,\\text{mL/min}$\n- Target for patient $2$: average steady-state plasma concentration for patient $2$, $C_{ss,\\text{avg},2}$, must equal that of patient $1$, $C_{ss,\\text{avg},1}$.\n- Assumption $1$: At steady state, average concentration is proportional to dosing rate and inversely proportional to clearance: $C_{ss,\\text{avg}} = \\frac{F \\cdot D / \\tau}{CL}$.\n- Assumption $2$: Pregabalin is eliminated unchanged by the kidney with negligible nonrenal clearance.\n- Assumption $3$: Total body clearance ($CL$) scales linearly with creatinine clearance ($CL_{Cr}$).\n- Assumption $4$: Oral bioavailability ($F$) is constant across the two patients.\n- The objective is to find the single dose $D_2$ for patient $2$.\n- The final answer should be rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated for validity:\n- **Scientifically Grounded:** The problem is based on fundamental principles of pharmacokinetics, specifically the relationship between dosing, clearance, and steady-state drug concentration. The method of adjusting a drug dose based on a patient's renal function (measured by creatinine clearance) is a standard and critical practice in clinical medicine, particularly for drugs like pregabalin that are primarily cleared by the kidneys. The assumptions provided are standard and scientifically sound.\n- **Well-Posed:** The problem is clearly stated, with all necessary data and relationships provided to determine a unique solution for the dose $D_2$.\n- **Objective:** The problem is expressed using precise, quantitative, and unbiased language.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid** as it is scientifically grounded, well-posed, and objective. A solution will be derived.\n\nThe average steady-state plasma concentration, $C_{ss,\\text{avg}}$, is defined by the rate of drug administration divided by the total body clearance, $CL$. The rate of administration is the dose $D$ multiplied by its oral bioavailability $F$, all divided by the dosing interval $\\tau$.\n\n$$ C_{ss,\\text{avg}} = \\frac{\\text{Dosing Rate}}{CL} = \\frac{(F \\cdot D) / \\tau}{CL} = \\frac{F \\cdot D}{CL \\cdot \\tau} $$\n\nFor patient $1$, with dose $D_1$ and total body clearance $CL_1$, the average steady-state concentration is:\n$$ C_{ss,\\text{avg},1} = \\frac{F \\cdot D_1}{CL_1 \\cdot \\tau} $$\n\nFor patient $2$, with the new dose $D_2$ and total body clearance $CL_2$, the concentration is:\n$$ C_{ss,\\text{avg},2} = \\frac{F \\cdot D_2}{CL_2 \\cdot \\tau} $$\n\nThe objective is to maintain the same average steady-state concentration for both patients, so we set $C_{ss,\\text{avg},1} = C_{ss,\\text{avg},2}$:\n$$ \\frac{F \\cdot D_1}{CL_1 \\cdot \\tau} = \\frac{F \\cdot D_2}{CL_2 \\cdot \\tau} $$\n\nThe oral bioavailability $F$ and the dosing interval $\\tau$ are constant for both patients and are non-zero, so they cancel from the equation:\n$$ \\frac{D_1}{CL_1} = \\frac{D_2}{CL_2} $$\n\nThis equation shows that to maintain a constant average concentration, the dose must be adjusted in direct proportion to the patient's drug clearance.\n\nThe problem states that pregabalin has negligible nonrenal clearance and its total body clearance, $CL$, scales linearly with creatinine clearance, $CL_{Cr}$. This can be expressed as a direct proportionality:\n$$ CL = k \\cdot CL_{Cr} $$\nwhere $k$ is a constant of proportionality that depends on the specific drug and physiological factors but is the same for both individuals under the model's assumptions.\n\nSubstituting this relationship into our dose-clearance equation for both patients:\n$CL_1 = k \\cdot CL_{Cr,1}$\n$CL_2 = k \\cdot CL_{Cr,2}$\n\nThe equation becomes:\n$$ \\frac{D_1}{k \\cdot CL_{Cr,1}} = \\frac{D_2}{k \\cdot CL_{Cr,2}} $$\n\nThe constant of proportionality $k$ is also non-zero and cancels out, simplifying the relationship to a direct ratio of doses and creatinine clearances:\n$$ \\frac{D_1}{CL_{Cr,1}} = \\frac{D_2}{CL_{Cr,2}} $$\n\nWe need to solve for the adjusted dose, $D_2$. Rearranging the equation:\n$$ D_2 = D_1 \\cdot \\frac{CL_{Cr,2}}{CL_{Cr,1}} $$\n\nNow, we substitute the given numerical values:\n$D_1 = 150\\,\\text{mg}$\n$CL_{Cr,1} = 100\\,\\text{mL/min}$\n$CL_{Cr,2} = 30\\,\\text{mL/min}$\n\n$$ D_2 = 150\\,\\text{mg} \\cdot \\frac{30\\,\\text{mL/min}}{100\\,\\text{mL/min}} $$\n$$ D_2 = 150 \\cdot 0.3\\,\\text{mg} $$\n$$ D_2 = 45\\,\\text{mg} $$\n\nThe problem requires the answer to be rounded to three significant figures. The calculated value $45$ can be expressed as $45.0$ to meet this requirement.", "answer": "$$\\boxed{45.0}$$", "id": "4966189"}]}